308 related articles for article (PubMed ID: 32043915)
1. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
2. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
3. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Abbasi IA
Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
[TBL] [Abstract][Full Text] [Related]
4. Timing and optimized acquisition parameters for the whole-body imaging of ¹⁷⁷Lu-EDTMP toward performing bone pain palliation treatment.
Liu C; Brašić JR; Liu X; Li H; Xiang X; Luo Z; Wang Y; Kuai D; Zhang G; Zaknun JJ
Nucl Med Commun; 2012 Jan; 33(1):90-6. PubMed ID: 22001721
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
Guerra Liberal FD; Tavares AA; Tavares JM
Med Phys; 2014 Nov; 41(11):114101. PubMed ID: 25370676
[TBL] [Abstract][Full Text] [Related]
7. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188
[TBL] [Abstract][Full Text] [Related]
10. Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153.
Guerra Liberal FDC; Tavares AAS; Tavares JMRS
Appl Radiat Isot; 2016 Apr; 110():87-99. PubMed ID: 26773820
[TBL] [Abstract][Full Text] [Related]
11. Studies on the Labeling of Ethylenediaminetetramethylene Phosphonic Acid, Methylene Diphosphonate, Sodium Pyrophosphate and Hydroxyapatite with Lutetium-177 for use in Nuclear Medicine.
Abbasi IA
World J Nucl Med; 2015; 14(2):95-100. PubMed ID: 26097419
[TBL] [Abstract][Full Text] [Related]
12. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
[TBL] [Abstract][Full Text] [Related]
14. Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP.
Bianchi L; Baroli A; Marzoli L; Verusio C; Chiesa C; Pozzi L
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):122-9. PubMed ID: 18751975
[TBL] [Abstract][Full Text] [Related]
15.
Askari E; Harsini S; Vahidfar N; Divband G; Sadeghi R
Cancer Biother Radiopharm; 2021 Jun; 36(5):383-390. PubMed ID: 33259726
[No Abstract] [Full Text] [Related]
16. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
17.
Alavi M; Khajeh-Rahimi F; Yousefnia H; Mohammadianpanah M; Zolghadri S; Bahrami-Samani A; Ghannadi-Maragheh M
Cancer Biother Radiopharm; 2019 Jun; 34(5):280-287. PubMed ID: 30977670
[No Abstract] [Full Text] [Related]
18. Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience.
Mostafa MYA; Zakaly HMH; Tekin HO; Issa SAM; Erdemir RU; Zhukovsky M
Appl Radiat Isot; 2021 Oct; 176():109841. PubMed ID: 34214913
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
